N-methyl-D-aspartate glutamate receptor (NMDA-R) antagonists produce schizophrenia-like positive and negative symptoms in healthy human subjects. Preclinical research suggests that NMDA-R antagonists interfere with the function of gamma-aminobutyric acid (GABA) neurons and alter the brain oscillations. These changes have been hypothesized to contribute to psychosis. In this investigation, we evaluated the hypothesis that the NMDA-R antagonist ketamine produces alterations in cortical functional connectivity during rest that are related to symptoms. We administered ketamine to a primary sample of 22 subjects and to an additional, partially overlapping, sample of 12 subjects. Symptoms before and after the experimental session were rated with the Positive and Negative Syndrome Scale (PANSS). In the primary sample, functional connectivity was measured via functional magnetic resonance imaging almost immediately after infusion began. In the additional sample, this assessment was repeated after 45 min of continuous ketamine infusion. Global, enhanced functional connectivity was observed at both timepoints, and this hyperconnectivity was related to symptoms in a region-specific manner. This study supports the hypothesis that pathological increases in resting brain functional connectivity contribute to the emergence of positive and negative symptoms associated with schizophrenia.
INTRODUCTION
N-methyl-D-aspartate glutamate receptor (NMDA-R) antagonist drugs induce psychosis in healthy humans. [1] [2] [3] [4] [5] [6] NMDA-R antagonists produce symptoms more closely resembling the positive and negative symptoms of schizophrenia than do amphetamine or serotonergic hallucinogens. 1, [4] [5] [6] [7] The degree to which ketamine produces negative symptoms is related to the degree of its occupancy of NMDA-R receptors. 8 Other neuroimaging data suggest that the production of schizophrenia-like symptoms by ketamine is associated with frontal cortical activation, as suggested by increased frontal cortical perfusion, [9] [10] [11] cortical glucose metabolism, 12, 13 and glutamate levels.
14 NMDA-R antagonists increase cortical activation and alter brain functional connectivity by inhibiting NMDA-Rs on gamma-aminobutyric acid (GABA) interneurons within local circuits. [15] [16] [17] [18] NMDA-R inhibition of GABA interneurons and disinhibition of pyramidal neurons are consistent with the reductions of extracellular GABA levels and elevations of extracellular glutamate levels. [19] [20] [21] Further, cognitive and behavioral effects of NMDA-R antagonists may be reduced by facilitating GABA neurotransmission 22 or by reducing glutamatergic hyperactivation. [23] [24] [25] NMDA-R antagonists also increase cortical high frequency or gamma oscillations in animals, an effect hypothesized to contribute to psychosis. 26, 27 Recent pharmacogenetic and optogenetic studies of the hippocampus elegantly show that inactivation of somatostatin, but not parvalbumin GABA neurons increases cortical gamma oscillations. 28, 29 Thus, NMDA-R antagonists may produce a pathological increase in cortical oscillations by inhibiting the activation of subpopulations of GABA interneurons.
In this study, we test the hypothesis that positive and negative symptoms produced by NMDA-R antagonists emerge in the context of altered brain functional connectivity as measured by functional magnetic resonance imaging (fMRI). In searching for connectivity alterations, we collected fMRI data during resting on and off ketamine, and analyzed it using a relatively new technique called 'global-based connectivity' (GBC). [30] [31] [32] It assesses the correlational strength of each voxel with all the other voxels in the brain. Though GBC represents a global measure of each voxel's connectivity, particular cortical regions can have greater global connectivity than others. Thus, GBC was originally developed to detect areas of high connectivity or 'hubs' in the brain. 30 In this investigation, we used GBC to assess whether ketamine induces region-specific or overall changes in connectivity and whether these changes would relate to ketamine-evoked psychiatric symptoms.
MATERIALS AND METHODS Participants
of ketamine infusion from an additional sample of 12 healthy volunteers (6 male, ages 22-45, all right-handed). This second sample included four individuals from the initial sample. All subjects in both samples denied a history of neurological disorder, substance abuse or dependence, or other psychiatric illness, and did not have a first degree relative with substance abuse or psychiatric history. The protocol was approved by the Yale Human Investigations Committee and the Western Institutional Review Board. All subjects provided written informed consent.
Procedures
Screening. Subjects were assessed using a structured interview for diagnosing psychiatric disorder, Structured Clinical Interview for DSM-III-R Non-Patient. 33 Psychotic-like symptoms were assessed with the PerceptualAberration-Magical Ideation and the Revised Social Anhedonia Scale. [34] [35] [36] Descriptive statistics are displayed in Table 1 . First degree family history of psychiatric disorder was assessed with the Family History Assessment Module. 37 An outside informant (typically a spouse, parent or close relative) was asked to verify psychiatric, substance abuse and medical history. Participants received a physical exam including urine drug screen, breathalyzer test, full blood count, and clinical chemistry. They were eliminated if they were not in good physical health, had an Axis I psychiatric disorder or a first degree relative with an Axis I psychiatric disorder or scored higher than two s.d. above the norm on the tests of psychotic-like symptoms.
Imaging day. Participants who passed screening were scheduled for an experimental session. Female subjects were scheduled so they were in the follicular phase, if at all possible. On the morning of the scan, participants were assessed with the Positive and Negative Syndrome Scale (PANSS). 38 Two intravenous catheters were placed: one for infusing saline and later ketamine, and another for drawing blood samples. Participants were placed in a 3 Tesla Trio scanner (Siemens Medical Solutions, Malvern, PA, USA). The subjects in the primary sample were scanned with a volume coil and the additional sample was scanned after a total imaging matrix upgrade. Each subject's pulse, respiration, oxygen saturation and heart rate were monitored throughout the scanning session.
After acquisition of structural images, functional imaging commenced with a visual fixation scan during which participants looked at a projected cross. Stimuli were back-projected onto a mirror. Seventy-five seconds into the scan, participants received a saline bolus. They then received a constant saline infusion and completed eight task scans lasting B40 min. Results related to task will be reported elsewhere.
Following these saline infusion scans, the visual fixation scan and eight task scans were repeated with ketamine infusion. The initial ketamine bolus was 0.23 mg kg À 1 over 1 min and the subsequent constant infusion was 0.58 mg kg À 1 per h. The total ketamine infusion time was B45 min and the volume of the saline bolus and infusion were comparable with that of the ketamine bolus and infusion. Blood samples were taken B5, 25 and 45 min after the start of each bolus. Ketamine levels were later determined by a previously published method. 39 The entire scanning session lasted B2-2.5 h. The additional sample of 12 subjects received, after the final task scan, an extra resting scan with continued constant ketamine infusion. Afterwards, participants were removed from the scanner and reassessed with the PANSS. Ratings considered their entire ketamine experience. Each subject completed 18 scans of 166 image volumes including six initial images that were later discarded. The same acquisition sequence was used for task and resting runs.
Imaging analysis. Preprocessing and primary analyses were conducted with the FMRIB Software Library (http://www.fmrib.ox.ac.uk/fsl). Global connectivity was computed in Analysis of Functional Images (AFNI). 40 The maps correlating performance and PANSS symptoms with connectivity alterations were computed with custom software written for this purpose. All maps were corrected for multiple comparisons with 3dClustSim, a cluster correction procedure available in the AFNI. The program determined a minimum cluster size with Monte Carlo simulation, so as to achieve a corrected significance of Po0.05 with a voxelwise threshold of Po0.05.
Preprocessing. In brief, data were converted into Neuroimaging Informatics Technology Initiative format, and brain extraction was performed to delete non-brain elements. 41 Then images were corrected to the middle image of the run for motion using MCFLIRT(motion correction using FMRIB's linear image registration tool), 42 corrected for slice-timing, smoothed with a Gaussian kernel of full width half maximum 5 mm and normalized with a single multiplicative factor. Voxelwise temporal autocorrelation was estimated and corrected using FMRIB's Improved Linear Model 43 Images used in the analyses reported here were low-pass filtered with a cut off frequency of 0.08 Hz. Registration was achieved by coregistering each individual's coplanar image to their high-resolution structural scan. Then the high-resolution structural scan was coregistered to the Montreal Neurologic Institute standard brain supplied with FMRIB's Software Library.
Runs with motion42 mm in the x, y or z direction or43 degrees of pitch, yaw or roll were eliminated. In the entire sample, a total of two runs were eliminated. Motion correction parameters derived on an individual basis were converted to measures of absolute distance from the center of the brain. These measures were analyzed and no statistically significant differences related to drug were found.
Connectivity analyses. To examine global changes in connectivity under ketamine, we conducted a whole-brain connectivity analysis using the AFNI (http://afni.nimh.nih.gov/afni) instacorr function that computes the correlation between each voxel and all the other voxels in the brain and returns an average correlation for each voxel. To compare the global connectivity score distributions under saline and ketamine, we first created a statistical map at the group level representing their difference. We then computed a onesample t-test on all the brain voxels. Because of the very large sample (4220 000 voxels), the test statistic is reported as a z ,and effect sizes are included. In order to achieve a relatively stable ketamine level, we used the last 50 images of the saline and ketamine bolus scans (primary subject sample). As ketamine levels were stable throughout the entire scan, the entire ketamine scan was compared with the entire saline bolus scan for the analysis of resting data collected after 45 min of ketamine infusion (additional sample). The effect sizes for the initial and repeat resting periods are not directly comparable because they were computed on 50 and 160 images per condition, respectively.
We performed analyses relating GBC to the positive, negative and cognitive factors 44 of the PANSS. 'Positive' refers to psychotic-like symptoms, 'negative' to social withdrawal and blunted affect, and 'cognitive' to thought disorder and poor concentration. We chose these three factors because they have most consistently emerged in factor analyses. [45] [46] [47] [48] To assess whether overall changes in GBC were related to PANSS factor scores, we counted the number of voxels in an individuals' saline and ketamine maps whose z score was higher than 1.96 and subtracted the saline voxel count from the ketamine voxel count. This connectivity measure was then correlated with each of the PANSS factors scores.
To assess whether region-specific changes in GBC were related to PANSS factors scores, we created statistical maps depicting the correlation between change in an outcome variable (positive, negative or cognitive factor score) and each voxel's GBC change. The resulting correlation maps were then converted to p-maps and cluster corrected. All clusters were screened for outliers by graphing individual's average connectivity change score for a cluster against their outcome variable score. No outliers were found. Figure 1a . This increase occurred across all voxels in the brain, and further examination indicated no discrete clusters of increased GBC within this overall pattern (Figures 1b and c) . This overall hyperconnectivity was also observed in an additional fMRI rest acquisition obtained after 45 min of ketamine infusion in a supplemental sample of 12 individuals (Figure 1d, z ¼ 4.03, Po0.0001, d 0 ¼ 0.85). Ketamine increased negative, positive and cognitive symptoms as measured by the PANSS (Figure 2 ). There was no statistically significant relationship between the number of voxels with increased GBC under ketamine and ketamine blood plasma levels measured after the bolus scan nor was there a relationship with PANSS factor scores. However, analysis of the statistical maps, in which the individual voxel's GBCs were correlated with symptom scores revealed region-specific relationships between GBC and positive and negative, but not cognitive symptoms.
Region-specific areas in which GBC changes predicted symptoms consisted of six clusters related to positive symptoms and one cluster related to negative symptoms. Many regions identified by GBC predicted positive symptoms (r ¼ 0.56-0.65; Table 2 , Figure 3 ). The most extensive cluster ranged from orbital frontal cortex to anterior cerebellar vermis. Within this cluster, the structures whose change in GBC was most closely associated with positive symptoms (Po0.01) were the right insula, right planum temporale, bilateral pulvinar nuclei, left lingual gyrus and anterior cerebellar vermis. In all clusters, increases in GBC were associated with increased positive symptoms. In contrast to the extensive brain areas correlated with positive symptoms, areas related to negative symptoms were quite circumscribed. Individuals who, under ketamine, increased GBC in the dorsal and medial anterior striatum and the thalamus (area of the ventral lateral nucleus) were less likely to experience negative symptoms than individuals who had stable or decreased GBC in these regions (r ¼ À 0.63, Figure 4 ).
DISCUSSION
The primary finding from this study is that ketamine increased overall brain GBC. The finding that ketamine increased GBC at rest may be consistent with other evidence that NMDA-R antagonists increase gamma oscillations. 26, 27, 49, 50 The increase in resting GBC was a relatively stable feature of ketamine effects on the brain, as it was observed when sampled almost immediately after ketamine infusion began and was present after 45 min of ketamine infusion.
Also, regionally-specific increases in GBC produced by ketamine were linked to positive and negative, but not cognitive symptoms. However, the negative finding regarding cognitive symptoms is best considered equivocal, because we lacked a detailed, neurocognitive assessment during ketamine infusion. Overall, the findings in this paper illustrate the complexity of the relationship between GBC and symptoms. Had there been a uniform relationship between GBC and symptom changes, this study would have supported the hypothesis that GBC was a simple biomarker for symptoms. But this was not the case. In the current study, some increases in GBC produced by ketamine were markers of network dysfunction, psychosis in this case, perhaps reflecting pathological synchrony in networks that are normally more functionally distinct. In the current study, many of the hypersynchronous regions are implicated in interoceptive and/or exteroceptive sensory processing, suggesting a link between psychosis and abnormal sensory processing. [51] [52] [53] [54] [55] In contrast, increased GBC in a few, circumscribed areas was associated with reduced negative symptoms, suggesting that increased GBC under ketamine was related to enhanced cortical function rather than pathology. These areas were in the thalamus and striatum and were closely associated with frontal cortex, specifically middle frontal gyrus, the frontal eye fields, premotor areas and the anterior cingulate. [56] [57] [58] Increased GBC in these areas may have reflected enhanced functional connectivity within cortico-striatal-thalamic circuits. Thus, inferences about the functional significance of changes in GBC must consider both spatial localization and functional correlates.
This study has limitations that influence interpretation of the study results. First, ketamine has secondary sites of action unrelated to blockade of NMDA-R. [59] [60] [61] However, its effects of interest are attributed to occupancy of NMDA receptors 8 and persist despite blockade of dopamine D2 62 and opiate 63 receptors. For this reason, ketamine produces effects on cortical networks closely resembling more selective NMDA-R antagonists. 27 Second, we did not include a detailed, neurocognitive assessment under ketamine. This may have precluded our detecting a relationship between cognitive symptoms and GBC. Third, in seeking to understand ketamine's effects, we interrogated connectivity alterations in large areas of the brain and related them to symptoms, raising the possibility of false positives. To counteract this, we used a relatively new technique, GBC, that is designed to allow consideration of all brain voxels and complemented it with well-validated PANSS factor solutions and cluster correction of all statistical maps to the highest of current standards.
In conclusion, the NMDA-R antagonist ketamine increased GBC in healthy human subjects. In many circuits, increased GBC was positively correlated with psychosis. However, in a cortical-striatialthalamic circuit related to prefrontal cortex, increased GBC was correlated with reduced negative symptoms during ketamine. Thus, GBC is a sensitive measure of functional changes in glutamate synaptic connectivity, supporting its potential utility as a biomarker of glutamatergic synaptic dysfunction.
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